Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.06. | INVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors | 445 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), June 10, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
27.05. | INVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference | 306 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), May 27, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
23.05. | Inventiva S.A. reports Q1 results | 1 | Seeking Alpha | ||
23.05. | INVENTIVA: Inventiva reports 2025 First Quarter Financial Information | 351 | GlobeNewswire (Europe) | Cash and cash equivalents at €67.9 million
Daix (France), New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
23.05. | INVENTIVA: Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 | 170 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
22.05. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
22.05. | Inventiva sets share repurchase program terms post-meeting | 5 | Investing.com | ||
INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
22.05. | INVENTIVA: Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux | 254 | GlobeNewswire (Europe) | Daix, May 22, 2025
Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l'Autorité des marchés financiers), the purpose of this description is to present the objectives... ► Artikel lesen | |
05.05. | Inventiva secures €116 million second tranche of structured financing of up to €348 million | 2 | Seeking Alpha | ||
05.05. | INVENTIVA: Inventiva secures the €116 million second tranche of its structured financing of up to €348 million | 344 | GlobeNewswire (Europe) | Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions.
Daix (France), New York City (New York, United... ► Artikel lesen | |
02.05. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
30.04. | INVENTIVA: Statement of total voting rights and shares forming the company's share capital as of April 11, 2025 | 247 | GlobeNewswire (Europe) | Article R. 22-10-23 of the French Commercial Code
Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com
DateNumber of shares outstandingTotal voting rights... ► Artikel lesen | |
30.04. | INVENTIVA: Combined General Meeting of May 22, 2025 - Availability of the preparatory documents | 274 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), April 30, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small... ► Artikel lesen | |
24.04. | INVENTIVA: Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor | 321 | GlobeNewswire (Europe) | ? Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis
? The biomarker signatures developed for fibrosis improvement... ► Artikel lesen | |
24.04. | Inventiva S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
15.04. | INVENTIVA: Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F | 663 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), April 15, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
15.04. | Inventiva S.A. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
11.04. | Inventiva S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
04.04. | Guggenheim cuts Inventiva stock target to $9, maintains Buy rating | 1 | Investing.com | ||
02.04. | Inventiva stock rises following NATiV3 trial enrollment completion | 3 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AURORA CANNABIS | 3,540 | +0,28 % | Aurora Cannabis Inc (3): Aurora Cannabis expands compassionate pricing program | ||
CANOPY GROWTH | 1,036 | -0,19 % | Canopy Growth Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
TILRAY BRANDS | 0,344 | +0,09 % | Tilray Brands, Inc.: Tilray Medical erhält vom italienischen Gesundheitsministerium die erste Genehmigung für den Vertrieb von medizinischen Cannabisblüten für therapeutische Zwecke | SAVONA, Italien, June 25, 2025 (GLOBE NEWSWIRE) -- Tilray Medical ("Tilray"), ein Geschäftsbereich von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY) und weltweit führender Anbieter von medizinischem... ► Artikel lesen | |
TEVA | 14,300 | -0,35 % | Teva Pharmaceutical Industries Ltd: Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY (fremanezumab) für die Prävention chronischer und episodischer Migräne | Die abschließende Analyse der realen PEARL-Studie für die Migräneprävention wurde auf dem 11. Kongress der European Academy of Neurology (EAN 2025) in Helsinki präsentiert1,2Fremanezumab demonstrierte... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 378,70 | +0,49 % | Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug | ||
ARZNEIWERK AG VIDA | 0,575 | -5,74 % | PTA-News: Arzneiwerk AG VIDA: Börsenzulassung von 226.155 Aktien | DJ PTA-News: Arzneiwerk AG VIDA: Börsenzulassung von 226.155 Aktien
Unternehmensmitteilung für den Kapitalmarkt
Arzneiwerk AG VIDA: Börsenzulassung von 226.155 Aktien
Berlin (pta000/16.06.2025/12:00... ► Artikel lesen | |
CRONOS GROUP | 1,614 | -0,31 % | Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders | TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June... ► Artikel lesen | |
VIATRIS | 7,772 | +0,54 % | Viatris Reports Positive Data From Presbyopia Study | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS), Thursday announced positive top-line results from VEGA-3, evaluating MR-141 in patients with presbyopia, the progressive loss of the ability to focus... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 8,400 | +1,89 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
INCYTE | 60,88 | +4,21 % | Leichte Zugewinne bei der Incyte-Aktie (60,38 €) | Im US-amerikanischen Wertpapierhandel liegt die Incyte-Aktie aktuell im Plus. Das Wertpapier notiert zur Stunde bei 60,38 Euro. Am US-amerikanischen Aktienmarkt hat sich heute die Incyte-Aktie zwischenzeitlich... ► Artikel lesen | |
BAUSCH HEALTH | 5,500 | -0,25 % | Bausch Health Companies Inc. - 8-K, Current Report | ||
EDWARDS LIFESCIENCES | 66,19 | -0,97 % | Kurs der Edwards Lifesciences-Aktie verharrt auf Vortags-Niveau (66,0969 €) | An der US-amerikanischen Börse ist die Aktie von Edwards Lifesciences derzeit unauffällig. Die Aktie notiert gegenwärtig bei 75,94 US-Dollar. Kaum auffällig ist zur Stunde am Aktienmarkt der Kurs von... ► Artikel lesen | |
IONIS PHARMACEUTICALS | 34,010 | +0,06 % | H.C. Wainwright bestätigt Kaufempfehlung für Ionis Pharmaceuticals-Aktie bei 50 US-Dollar | ||
CRESCO LABS | 0,450 | +6,18 % | Cresco Labs Inc: Cresco Labs terminates auditor Marcum | ||
BAYER | 26,975 | +2,64 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
23.06.2025... ► Artikel lesen |